GlassScriptPhysician profile
Ronald J Robinson
NPI 1881701555
$5,817.93
in general payments reported to CMS, 2019-2025
29 companies · $726 in 2025
The $726 reported for 2025 was more than what 93% of Hospitalist providers received nationally (typical 2025 total: $85.87).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $113 · 2020: $1,175 · 2021: $1,497 · 2022: $962 · 2023: $660 · 2024: $686 · 2025: $726.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,072.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,071.57 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $1,048.16 | 2019-2025 | |
| Glaxosmithkline, LLC. | $917.94 | 2020-2025 | Shingrix, Trelegy Ellipta, Arexvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $687.49 | 2019-2025 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $519.84 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Janssen Pharmaceuticals, INC | $518.17 | 2019-2022 | |
| Lilly USA, LLC | $440.87 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Abbvie INC. | $389.50 | 2020-2023 | Vraylar |
| Gilead Sciences, INC. | $185.85 | 2020-2022 | |
| Novo Nordisk INC | $144.36 | 2019-2025 | |
| Radius Health, INC. | $90.95 | 2022-2025 | Tymlos |
| Aimmune Therapeutics, INC. | $87.36 | 2025 | Zenpep |
| Merck Sharp & Dohme LLC | $87.31 | 2023-2025 | Gardasil 9, Capvaxive, Gardasil |
| E.R. Squibb & Sons, L.L.C. | $85.14 | 2020-2021 | |
| Sanofi-Aventis U.S. LLC | $80.93 | 2020-2021 | |
| Astellas Pharma US INC | $73.51 | 2023-2024 | Veozah |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nestle Healthcare Nutrition INC. | $73.07 | 2021-2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $72.39 | 2022 | |
| Seqirus USA INC | $37.31 | 2020-2025 | Flucelvax |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $36.58 | 2020 | |
| Dexcom, INC. | $30.45 | 2025 | Dexcom G6 Transmitter |
| Kyowa Kirin, INC. | $29.21 | 2022 | |
| Kowa Pharmaceuticals America, INC. | $24.88 | 2024 | Zoryve |
| Bayer Healthcare Pharmaceuticals INC. | $24.40 | 2022 | |
| Amarin Pharma, INC. | $23.68 | 2021 | |
| Scilex Pharmaceuticals INC. | $23.02 | 2023 | Ztlido |
| Exact Sciences Corporation | $22.91 | 2024 | Cologuard Collection Kit |
| Ironwood Pharmaceuticals, INC | $21.52 | 2020 | |
| Idorsia Pharmaceuticals US INC | $21.20 | 2023 | Quviviq |
| Novavax INC | $19.93 | 2024 | Novavax Covid-19 Vaccine, Adjuvanted |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Robinson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.